Cargando…

ATRT-24. CDK7 Inhibition in AT/RT

Atypical teratoid/rhabdoid tumors (AT/RT) are CNS tumors with a 5-year survival of ~35%. AT/RT is characterized by loss-of-function mutations in the SMARCB1 component of the SWI/SNF (SWItch/Sucrose Non-Fermentable) complex. Based on preliminary CRISPR-Cas9 gene essentiality screen results identifyin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morin, Andrew, Wodetzki, Darya, Veo, Bethany, Pierce, Angela, Zahedi, Shadi, Crespo, Michele, Venkataraman, Sujatha, Vibhakar, Rajeev, Mulcahy-Levy, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Atypical Teratoid Rhabdoid Tumor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164859/ http://dx.doi.org/10.1093/neuonc/noac079.023

Ejemplares similares

ATRT-20. CDK7 INHIBITION IN AT/RT
por: Morin, Andrew, et al.
Publicado: (2020)

ATRT-23. SIRT2 cooperates with SMARCB1 to induce a differentiation block in ATRT
por: Alimova, Irina, et al.
Publicado: (2022)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT)
por: Alimova, Irina, et al.
Publicado: (2020)

ATRT-24. CELL SURFACE PROTEOME ANALYSIS OF ATRT IDENTIFIES TARGETS FOR IMMUNOTHERAPY
por: Cole, Allison, et al.
Publicado: (2020)

ATRT-19. Functional genomics reveal distinct modulators of response to CDK4/6 inhibitors in ATRTs
por: Merk, Daniel, et al.
Publicado: (2022)

ATRT-10. Single-cell transcriptional profiling of ATRTs reveals heterogeneous signatures of tumor and non-malignant cell populations
por: Blanco-Carmona, Enrique, et al.
Publicado: (2022)

ATRT-19. EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT
por: Hariharan, Seethalakshmi, et al.
Publicado: (2020)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

ATRT-33. ENABLING RAPID CLASSIFICATION OF ATRT WITH NANOSTRING NCOUNTER PLATFORM
por: Ho, Ben, et al.
Publicado: (2020)

ATRT-27. COST-EFFECTIVE ASSAYS TO SUBGROUP ATRT IN THE DAILY ROUTINE
por: Lobon-Iglesias, María-Jesús, et al.
Publicado: (2020)

ATRT-14. MACROPHAGE-TUMOR CELL INTERACTION PROMOTES ATRT PROGRESSION AND CHEMORESISTANCE
por: Melcher, Viktoria, et al.
Publicado: (2020)

ATRT-28. SINGLE NUCLEI SEQUENCING REVEALS THE DIFFERENT PHENOTYPIC COMPOSITION OF THE ATRT SUBGROUPS
por: Johann, Pascal, et al.
Publicado: (2020)

ATRT-05. REPURPOSED ANTI-MALARIAL QUINACRINE ACTIVATES P53 AND INHIBITS ATRT TUMORIGENICITY
por: Kaur, Harpreet, et al.
Publicado: (2021)

ATRT-31. SUCCESSFUL MULTIMODALITY MANAGEMENT OF ATRT OF THE LOWER DORSAL SPINE WITH SPINAL DROP METASTASIS
por: Biswas, Ahitagni, et al.
Publicado: (2020)

ATRT-15. LY6D – A CANDIDATE FOR NANOPARTICLE-BASED TARGETED THERAPIES OF ATRT
por: Hagemeier, Lea, et al.
Publicado: (2020)

ATRT-11. PREVALENCE OF GERMLINE VARIANTS IN SMARCB1 INCLUDING SOMATIC MOSAICISM IN AT/RT AND OTHER RHABDOID TUMORS
por: Shirai, Ryota, et al.
Publicado: (2020)

ATRT-25. INTEGRATED QUANTITATIVE SWATH-MS PROTEOMICS ANALYSIS OF ATRTs UNCOVERS NEW THERAPEUTIC OPPORTUNITIES
por: Finetti, Martina Anna, et al.
Publicado: (2020)

ATRT-16. MODELLING ATRT THROUGH SWI/SNF COMPLEX DEFICIENCY IN GENETICALLY-ENGINEERED MOUSE MODELS
por: Bondoc, Andrew, et al.
Publicado: (2020)

ATRT-13. An integrative analysis of the ATRT proteome unravels novel drug targets and refines molecular subgrouping
por: Johann, Pascal, et al.
Publicado: (2022)

ATRT-05. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMORS (ATRT) OF THE CENTRAL NERVOUS SYSTEM
por: Zheludkova, Olga, et al.
Publicado: (2020)

ATRT-07. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AN ADULT PRESENTATION OF THE ATYPICAL TERATOID-RHABDOID TUMOR (ATRT)
por: Mrugala, Maciej, et al.
Publicado: (2020)

ATRT-06. Atypical Teratoid Rhabdoid Tumors (ATRT): results from a Single Institution in Brazil - São Paulo University
por: Barreto, Juliana Silveira, et al.
Publicado: (2022)

ATRT-11. Anatomico-biological correlations define a new layer for ATRT molecular subgroups pointing to potential lineages of origin
por: Lobon-Iglesias, Maria, et al.
Publicado: (2022)

ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population
por: Nemes, Karolina, et al.
Publicado: (2022)

ATRT-09. IDENTIFICATION OF POTENTIAL GENETIC DRIVERS OF METHOTREXATE (MTX) RESISTANCE IN ATYPICAL TERATOID RHABDOID TUMOURS (ATRT) THROUGH A GENOME-WIDE RNAI SCREEN
por: Kannappan, Sunand, et al.
Publicado: (2021)

ATRT-07. Low-grade diffusely infiltrative tumor, SMARCB1-mutant: a clinical and histopathological distinct entity showing epigenetic similarity with ATRT-MYC
por: Thomas, Christian, et al.
Publicado: (2022)

ATRT-01. Reconstitution of cGAS/ STING pathway via epigenetic reprogramming leads to anti-viral inflammatory signaling in Atypical teratoid rhabdoid tumors (ATRTs)
por: Mangoli, Avani, et al.
Publicado: (2022)

ATRT-02. THE DUAL MTORC1/2 INHIBITOR, TAK-228 COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC, OBATOCLAX TO IMPROVE SURVIVAL IN MICE BEARING ORTHOTOPIC XENOGRAFTS OF AT/RT
por: Findlay, Tyler, et al.
Publicado: (2021)

ATRT-02. MEK/ERK SIGNALLING DEPENDENCY IN ATYPICAL TERATOID RHABDOID TUMOURS
por: Shi, Hui (Claire), et al.
Publicado: (2020)

ATRT-10. ATYPICAL TERATOID/RHABDOID TUMOR OF THE PINEAL REGION IN A PEDIATRIC PATIENT
por: Almeida, Carlos, et al.
Publicado: (2020)

ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS
por: Graf, Monika, et al.
Publicado: (2020)

ATRT-18. Atypical Teratoid/Rhabdoid Tumor in Children: Case Reports from Indonesia
por: Ramadhan, Diko Anugrah, et al.
Publicado: (2022)

ATRT-23. THE DUAL mTORC1/2 INHIBITOR SAPANISERTIB DISRUPTS THE NRF2-MEDIATED STRESS RESPONSE AND COMBINES SYNERGISTICALLY WITH THE BH3 MIMETIC OBATOCLAX TO EXTEND AT/RT SURVIVAL
por: Parkhurst, Ashlyn, et al.
Publicado: (2020)

ATRT-09. IDENTIFICATION OF HUB GENES IN ATYPICAL TERATOID/RHABDOID TUMORS BY MULTIPLE-MICROARRAY ANALYSIS
por: Liu, Wei, et al.
Publicado: (2020)

ATRT-18. SHH-SUBTYPE ATYPICAL TERATOID/RHABDOID TUMORS ARE SELECTIVELY SENSITIVE TO GEMCITABINE TREATMENT
por: Metselaar, Dennis, et al.
Publicado: (2020)

ATRT-32. GENOME-WIDE CRISPR AND SMALL-MOLECULE SCREENS UNCOVER TARGETABLE DEPENDENCIES IN AT/RTs
por: Merk, Daniel, et al.
Publicado: (2020)

ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
por: Nesvick, Cody, et al.
Publicado: (2021)

ATRT-26. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN
por: Underiner, Reena M, et al.
Publicado: (2020)

ATRT-21. Contribution of germline mosaic alterations of SMARCB1 in rhabdoid tumor predisposition syndrome
por: Masliah-Planchon, Julien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eg75s031p1hco617l6pi4q7ath